<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Gemtuzumab is used to treat patients with previously untreated or recurrent <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The fludarabine and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C) regimen is active in these patients </plain></SENT>
<SENT sid="2" pm="."><plain>Resistance to gemtuzumab is associated with blast multidrug resistance (<z:chebi fb="14" ids="53218">MDR</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>The objectives of this study were to evaluate the efficacy and toxicity of a combination regimen of gemtuzumab, fludarabine, ara-C, and the <z:chebi fb="14" ids="53218">MDR</z:chebi> modifier (<z:chebi fb="0" ids="4031">cyclosporine</z:chebi> [CyA]) in patients with previously untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The MFAC regimen was comprised of gemtuzumab (Mylotarg trade mark ) (6 mg/m(2) intravenously [i.v.] on Day 1); fludarabine and ara-C (15 mg/m(2) and 0.5 g/m(2), respectively, twice daily on Days 2-6); and CSA (6 mg/kg loading dose before gemtuzumab, followed by 16 mg/kg continuous i.v. infusion on Days 1 and 2) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Fifty-nine evaluable patients were treated: 39 patients (66%) had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 20 patients (34%) had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Their median age was 57 years (range, 27-76 years) </plain></SENT>
<SENT sid="7" pm="."><plain>The MFAC regimen induced complete remission (CR) in 27 patients (46%) and CR with incomplete platelet recovery (CRp) in 1 patient (2%) </plain></SENT>
<SENT sid="8" pm="."><plain>The median survival period is 8 months </plain></SENT>
<SENT sid="9" pm="."><plain>At 12 months, the survival rate is 38% and the event-free survival rate in patients with CR/CRp is 27% </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> complicated 38% of the courses of chemotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>Grade 3/4 toxicity included <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in 31% and transaminitis in 7% of the patients </plain></SENT>
<SENT sid="12" pm="."><plain>Four patients (7%) developed <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">hepatic venoocclusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The MFAC regimen may merit further study in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> if measures to avoid and/or treat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> can be incorporated into the regimen </plain></SENT>
</text></document>